In this sense, our new results regarding IL-12 and IL-18 in vitro effect on KIR expression could indicate that in HC and MM patients combined IL-12 and IL-18 treatment by decreasing CD158b receptor MFI on NK cells and cytotoxic dim subset regulates NK cell responsiveness and effector function. This evidence concerns the gene IL18 and Miyoshi myopathy.